Poniard Pharmaceuticals 10K 2001 Annual report | PARD Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	7th grade Avg

New words: ABMTR, academic, accessed, accessing, ACS, acute, adenocarcinoma, adjacent, Adjunct, adult, ALCL, allocated, alongside, anaplastic, Anna, ascertained, aseptic, aspect, assumption, augment, avidity, bed, biodistribution, Bioscience, breakdown, broad, Brown, BS, burden, carcinoma, carefully, carrier, cellular, CEO, chaired, chance, chelating, chemotherapeutic, Chicago, children, chimeric, clearance, College, Commonwealth, complementary, composed, Conjunction, consummate, convened, core, Corixa, Council, CR, curative, cytostatic, cytotoxic, cytoxic, deadly, departure, detected, Diamond, Dickey, diffuse, Digestive, discontinued, disproportionate, disseminated, dissociation, distinguished, distinguishing, DLCL, DNA, documentation, domain, DOTA, DOTMP, durable, DVM, EITF, Elliott, entity, Epidemiology, eradicate, Estate, Ewing, excellent, excretory, expert, Extraordinary, extremely, FASB, feature, Fellow, Fellowship, fermentation, fill, filling, Findlay, firm, Foerster, follicular, Foundation, France, Franchise, Freiberg, fully, fundamental, galactose, GD, Genentech, Germany, Ghalie, GlaxoSmithKline, goodwill, gradually, Grantee, Grayson, Habilitation, heavily, Herceptin, Heun, historical, Hodgkin, Ia, Immunex, impaired, impairment, indolent, induce, inefficiency, Infrequently, inserting, instrument, Intangible, intercompany, interfering, intracellular, irradiation, JD, journalBlood, Kidney, land, leadership, leaving, Lebanon, Legendi, Les, Leslie, leukemia, Lewak, Lilly, Linda, lymphocyte, Mainz, maximize, MBA, measured, MedImmune, member, Mercator, merged, met, methodology, Michigan, microangiopathy, microbial, migrate, mitigate, mode, Monsanto, Morrison, multidisciplinary, multiplying, Muzak, naked, Neile, neurology, nominal, Norwood, notable, NRX, Nuclear, occasion, onset, organizational, Orphan, Oster, outpatient, ovarian, owed, PACCAR, Pacific, palliative, panel, pathogen, payload, peer, penetrate, penetration, Pennsylvania, pharmacokinetic, Pierce, pipeline, PLC, Political, poor, poorly, power, preliminary, prelocalized, pretreated, prevalent, prime, prioritizing, Pritzker, processing, Progenitor, purification, purity, radioimmunotherapeutic, radiolabeled, radiolabeling, radioresponsive, radiosensitive, radiosensitivity, radiotherapeutic, readily, Real, recombinant, refractory, Registry, relief, renal, replication, resistant, Resource, responded, resume, resumption, reveal, revised, Rituxan, Rituximab, Roche, rounding, Royal, Sabo, sarcoma, saturating, Science, Searle, seldom, Selig, separate, separately, separation, shift, Simpler, skeleton, slowly, smaller, sophisticated, Southern, sparing, Specialty, SPHR, Stability, stably, strong, Sublicense, substance, sugar, synthesized, tail, tangible, Task, team, Thousand, TMA, Trastuzumab, trend, turn, Tyco, UK, undesirable, unmet, Untreated, Unusual, updating, uptake, USPTO, variability, variable, Venia, versatile, VII, Virginia, Wall, Wayne, wealth, Wharton, widespread, Wight, Wolfgang, written, XI, Zevalin

Removed: agreed, attached, bacteria, began, bloodstream, bulky, bystander, cancelled, charge, clear, colon, combined, committed, constitute, decrease, Department, dislodge, display, engineered, faster, growing, hedge, hedging, hire, identical, imaging, improvement, Indemnification, indenture, inhibiting, injection, innocent, innovative, Interstate, intravenously, Janssen, Johnson, jurisdiction, kill, KPMG, letter, licensee, LLP, long, lung, lymph, manufactured, meaningful, metabolized, modest, moratorium, NV, observed, originate, paul, Pharmaceutica, preferentially, premium, Prepaid, principle, qualify, Radiology, reaching, reflecting, regression, reissue, relevant, remained, representative, repriced, requiring, resigning, restructured, restructuring, retired, return, safe, segregation, sensitive, sheet, Stanford, tendency, vitro, white, XXXXX, Yale

Poniard Pharmaceuticals (PARD) Inactive 10-K2001 FY Annual report

Content analysis